Trial Profile
An Observational Multi-cohort Study on the Use of Fosamprenavir-Ritonavir Among HIV-infected Children and Adolescents in Europe
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms PENTA Fosamprenavir
- Sponsors ViiV Healthcare
- 08 Feb 2012 Company (ViiV Healthcare) added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 03 Feb 2012 Additional location (United Kingdom) added and additional trial acronym (PENTA Fosamprenavir) identified as reported by ClinicalTrials.gov.
- 03 Feb 2012 Actual patient number (1) added as reported by ClinicalTrials.gov.